Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ESPR
stocks logo

ESPR

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
164.70M
+138.3%
0.279
-377.46%
109.49M
+68.45%
-0.007
-96.82%
99.63M
+20.93%
0.010
-150%
Estimates Revision
The market is revising Upward the revenue expectations for Esperion Therapeutics, Inc. (ESPR) for FY2025, with the revenue forecasts being adjusted by 5.86% over the past three months. During the same period, the stock price has changed by 41.42%.
Revenue Estimates for FY2025
Revise Upward
up Image
+5.86%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+369.89%
In Past 3 Month
Stock Price
Go Up
up Image
+41.42%
In Past 3 Month
Wall Street analysts forecast ESPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ESPR is 6.94 USD with a low forecast of 1.72 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
Wall Street analysts forecast ESPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ESPR is 6.94 USD with a low forecast of 1.72 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
1 Sell
Moderate Buy
Current: 3.790
sliders
Low
1.72
Averages
6.94
High
16.00
Current: 3.790
sliders
Low
1.72
Averages
6.94
High
16.00
Piper Sandler
David Amsellem
Overweight
initiated
$9
2025-11-25
Reason
Piper Sandler
David Amsellem
Price Target
$9
2025-11-25
initiated
Overweight
Reason
Piper Sandler analyst David Amsellem last night initiated coverage of Esperion with an Overweight rating and $9 price target. The company's bempedoic acid franchise for hypercholesterolemia and the reduction in associated cardiovascular disease risks positions it well for continued "rapid" volume and sales expansion, the analyst tells investors in a research note. Piper says its confidence is based on a "wide label," which includes primary prevention, evolving clinical practice guidelines, and wide payer access.
Piper Sandler
Overweight
initiated
$9
2025-11-24
Reason
Piper Sandler
Price Target
$9
2025-11-24
initiated
Overweight
Reason
Piper Sandler initiated coverage of Esperion with an Overweight rating and $9 price target.
Cantor Fitzgerald
Kristen Kluska
maintain
$7 -> $9
2025-09-25
Reason
Cantor Fitzgerald
Kristen Kluska
Price Target
$7 -> $9
2025-09-25
maintain
Reason
Cantor Fitzgerald analyst Kristen Kluska raised the firm's price target on Esperion to $9 from $7 and keeps an Overweight rating on the shares.
Goldman Sachs
Paul Choi
Hold
Maintains
$4 → $3
2025-04-17
Reason
Goldman Sachs
Paul Choi
Price Target
$4 → $3
2025-04-17
Maintains
Hold
Reason
Needham
Serge Belanger
Strong Buy
Reiterates
$5
2025-04-08
Reason
Needham
Serge Belanger
Price Target
$5
2025-04-08
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$16
2025-03-20
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$16
2025-03-20
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Esperion Therapeutics Inc (ESPR.O) is 12.55, compared to its 5-year average forward P/E of -1.97. For a more detailed relative valuation and DCF analysis to assess Esperion Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.97
Current PE
12.55
Overvalued PE
7.93
Undervalued PE
-11.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
11.74
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
121.73
Undervalued EV/EBITDA
-98.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.14
Current PS
0.00
Overvalued PS
5.77
Undervalued PS
0.51
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 7768.56% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 7768.56% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

ESPR News & Events

Events Timeline

(ET)
2025-11-21
08:12:59
Otsuka, Esperion's partner, introduces NEXLETOL in Japan
select
2025-11-18 (ET)
2025-11-18
07:13:27
Esperion announces that Health Canada has approved HLS to market NILEMDO.
select
2025-11-10 (ET)
2025-11-10
08:14:48
Esperion Reveals New Findings from CLEAR Outcomes Study on NEXLETOL
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-25SeekingAlpha
Piper Sandler Upgrades Esperion to Overweight Due to CV Franchise

  • Piper Sandler Coverage Initiation: Piper Sandler has initiated coverage of Esperion Therapeutics (ESPR) with an overweight rating, highlighting the potential for significant sales growth of its cholesterol-lowering drugs, Nexletol and Nexlizet, with a price target of $9, indicating a potential upside of approximately 184%.

  • Sales Projections and Market Position: The firm anticipates that peak US sales for the drugs could exceed $650 million, supported by exclusivity agreements and a favorable clinical landscape, including expanded labeling for primary and secondary prevention of cardiovascular events.

  • Cardiologist Survey Insights: A survey of cardiologists indicated that a significant portion believes the expanded label will enhance the role of Nexletol and Nexlizet in treatment options, with 35% expecting a notably greater role in patient care.

  • Recent Stock Performance: Following the positive coverage and market developments, Esperion shares experienced a ~16% increase in trading on Tuesday.

[object Object]
Preview
1.0
11-19Newsfilter
Esperion to Take Part in the 37th Annual Healthcare Conference Hosted by Piper Sandler

  • Company Presentation: Esperion will present at the Piper Sandler 37th Annual Healthcare Conference on December 3, 2025, at 3:30 p.m. ET, with a live webcast available on their website.

  • Focus on Cardiovascular Treatments: Esperion is a biopharmaceutical company specializing in FDA-approved oral medications for patients at risk of cardiovascular disease, particularly those with elevated LDL cholesterol.

  • Research and Development: The company is advancing its next-generation program aimed at developing ATP citrate lyase inhibitors (ACLYi), leveraging new insights for rational drug design.

  • Growth and Partnerships: Esperion is evolving into a leading global biopharmaceutical company through commercial execution, international collaborations, and the advancement of its pre-clinical pipeline.

[object Object]
Preview
9.0
11-18NASDAQ.COM
HLS, Esperion's Partner, Secures Health Canada Approval for NILEMDO to Reduce LDL Cholesterol

  • Health Canada Approval: HLS Therapeutics Inc. has received approval to market NILEMDO, a drug aimed at reducing LDL-cholesterol for individuals at risk of cardiovascular disease in Canada.

  • Commercial Launch Timeline: The commercial launch of NILEMDO is anticipated in the second quarter of 2026.

  • Heart Disease Statistics: Approximately 2.6 million Canadian adults, or one in 12 aged 20 and over, are diagnosed with heart disease, highlighting the need for effective treatments.

  • Author's Views Disclaimer: The opinions expressed in the article are those of the author and do not necessarily reflect the views of Nasdaq, Inc.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Esperion Therapeutics Inc (ESPR) stock price today?

The current price of ESPR is 3.79 USD — it has increased 0.26 % in the last trading day.

arrow icon

What is Esperion Therapeutics Inc (ESPR)'s business?

Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company. The Company is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.

arrow icon

What is the price predicton of ESPR Stock?

Wall Street analysts forecast ESPR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ESPR is 6.94 USD with a low forecast of 1.72 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Esperion Therapeutics Inc (ESPR)'s revenue for the last quarter?

Esperion Therapeutics Inc revenue for the last quarter amounts to 87.31M USD, increased 69.10 % YoY.

arrow icon

What is Esperion Therapeutics Inc (ESPR)'s earnings per share (EPS) for the last quarter?

Esperion Therapeutics Inc. EPS for the last quarter amounts to -0.16 USD, increased 6.67 % YoY.

arrow icon

What changes have occurred in the market's expectations for Esperion Therapeutics Inc (ESPR)'s fundamentals?

The market is revising Upward the revenue expectations for Esperion Therapeutics, Inc. (ESPR) for FY2025, with the revenue forecasts being adjusted by 5.86% over the past three months. During the same period, the stock price has changed by 41.42%.
arrow icon

How many employees does Esperion Therapeutics Inc (ESPR). have?

Esperion Therapeutics Inc (ESPR) has 304 emplpoyees as of December 05 2025.

arrow icon

What is Esperion Therapeutics Inc (ESPR) market cap?

Today ESPR has the market capitalization of 903.66M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free